Nanopath’s Trailblazing Diagnostics Platform for Women’s Health
Nanopath CEO Amogha Tadimety Recently Discussed Her Company on AV’s Tech Optimist Podcast
Alumni Ventures (AV), one of the world’s most active venture capital firms, is proud to support Nanopath, a trailblazing molecular diagnostics company focused on women’s health. In 2022, AV invested in Nanopath’s $10 million Series A led by Norwest Venture Partners and the Medtech Convergence Fund, an SV Health Investors Fund. The funding has helped to catalyze further development and commercialization of the company’s biosensing platform.
Nanopath Co-Founder and CEO Dr. Amogha Tadimety recently appeared on AV’s Tech Optimist podcast to discuss the company and her entrepreneurial journey.
“We are at a critical juncture in our journey to reshape women’s health diagnostics,” said Dr. Tadimety. “With support from firms like Alumni Ventures, we can accelerate our clinical pilot testing and scale our technology to meet the urgent needs of patients.”
Nanopath has developed a groundbreaking technology platform that enables rapid, amplification-free detection of DNAs or RNAs, delivering results in under 15 minutes. This innovation allows for immediate, actionable health insights during a single office visit, which is crucial for conditions commonly affecting women, such as urinary tract infections, STIs, and vaginitis.
AV’s investment in Nanopath was sponsored by Green D Ventures, the firm’s VC fund for the Dartmouth community. The Green D team built a strong relationship with Dr. Tadimety and Nanopath Co-Founder, President, and CTO Dr. Alison Burklund, who began developing Nanopath’s technology while earning their PhDs from Dartmouth’s Thayer School of Engineering.
“Nanopath represents exactly the kind of disruptive innovation we aim to support,” said AV Founder and CEO Mike Collins, who hosted the conversation with Tadimety on AV’s Tech Optimist podcast. “Their innovative technology can significantly improve the standard of care in women’s health diagnostics.”
Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. The company aims to improve the health of women by providing granular and clinically actionable information within a single office visit. Nanopath has built a novel nanosensor platform that harnesses advances in bioengineering and nanotechnology to detect viral, bacterial, and fungal pathogens without the need for nucleic acid amplification testing. The company is headquartered at The Engine in Cambridge, MA.
Alumni Ventures offers accredited individuals access to professional-grade venture capital, a key asset class missing from the portfolios of many sophisticated investors. Since 2014, AV has raised $1.3+ billion from 10,000+ investors and backed 1,300+ unique portfolio companies. AV is a top 20 venture firm in North America according to CB Insights, as well as the #1 most active venture firm in the U.S., and #3 most active in the world, according to PitchBook’s 2022 and 2023 rankings. AV has won awards from Inc. Magazine, Fast Company, Benzinga, and the US FinTech Awards.
